LABCORP HOLDINGS INC. (LH) — financial distillation

S&P 500 · United States · NYSE

LHCIK 0000920148Period ends 2026-06-30Distilled SEC EDGAR XBRL company facts

Annual history (10-K)

Quarterly history (10-Q)

Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.

In brief, from the full filed history

  • Revenue grew from $4.07B (period ending 2007-12-31) to $13.95B (period ending 2025-12-31) — a 7.1% annual pace across 18 year(s) of filed history.
  • Net margin compressed from 11.7% to 6.3% over that same span.
  • Across 53 tracked quarters, the strongest was $4.16B (quarter ending 2021-03-31) and the weakest was $1.14B (quarter ending 2008-09-30).

Annual — most recent 10-K

Line Value Period ends Form Filing
Revenue $13.95B 2025-12-31 10-K 0000920148-26-000111
Gross profit $4.01B 2025-12-31 10-K 0000920148-26-000111
Operating income $1.38B 2025-12-31 10-K 0000920148-26-000111
Net income $876.5M 2025-12-31 10-K 0000920148-26-000111
Diluted EPS $10.46 2025-12-31 10-K 0000920148-26-000111
Total assets $18.39B 2025-12-31 10-K 0000920148-26-000111
Total liabilities $9.76B 2025-12-31 10-K 0000920148-26-000111
Cash & equivalents $532.3M 2025-12-31 10-K 0000920148-26-000111
Operating cash flow $1.64B 2025-12-31 10-K 0000920148-26-000111

Quarterly — most recent 10-Q

Line Value Period ends Form Filing
Revenue $3.73B 2026-06-30 10-Q 0000920148-26-000175
Gross profit $1.11B 2026-06-30 10-Q 0000920148-26-000175
Operating income $451.6M 2026-06-30 10-Q 0000920148-26-000175
Net income $298.7M 2026-06-30 10-Q 0000920148-26-000175
Diluted EPS $3.64 2026-06-30 10-Q 0000920148-26-000175
Total assets $18.53B 2026-06-30 10-Q 0000920148-26-000175
Total liabilities $9.91B 2026-06-30 10-Q 0000920148-26-000175
Cash & equivalents $141.8M 2026-06-30 10-Q 0000920148-26-000175
Operating cash flow $191.5M 2026-03-31 10-Q 0000920148-26-000139

Reading

The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.

LabCorp Holdings Inc. (LH) operates in the clinical laboratory services sector, with a substantial scale evident from its annual revenue of $13.95 billion as of 2025-12-31. The company’s multi-year trajectory reveals steady growth, averaging a 7.1% annual pace over the past 18 years, as per the pre-computed trend facts. However, despite revenue expansion, net margins have contracted from 11.7% to 6.3% during this period.

The company’s financial performance indicates a focus on revenue generation, with quarterly revenues peaking at $4.16 billion in Q1 2021 and bottoming out at $1.14 billion in Q3 2008. This historical pattern underscores the volatility inherent in its business model. In terms of liquidity, LabCorp maintained $532.3 million in cash and equivalents as of 2025-12-31, though this figure has fluctuated over time.

In upcoming filings, investors should monitor the company’s ability to sustain revenue growth while addressing the shrinking net margins. Additionally, the management’s strategies to enhance operational efficiency and control costs will be crucial in determining future profitability and shareholder value.


Source: SEC EDGAR company facts for CIK 0000920148 · filings index